Daan Gene マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Luo Huang

最高経営責任者

CN¥1.3m

報酬総額

CEO給与比率	n/a
CEO在任期間	2.4yrs
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	2.5yrs

経営陣の近況

Recent updates

Health Check: How Prudently Does Daan Gene (SZSE:002030) Use Debt?

Oct 24

Daan Gene Co., Ltd. (SZSE:002030) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected

Aug 20

Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?

May 02

Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings

Apr 05

Calculating The Fair Value Of Daan Gene Co., Ltd. (SZSE:002030)

Mar 25

Daan Gene Co., Ltd. (SZSE:002030) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Mar 06

CEO（最高経営責任者

Luo Huang (44 yo)

2.4yrs

在職期間

CN¥1,266,800

報酬

Ms. Luo Huang is Non-Executive Director of Yunkang Group Limited from August 11, 2022. She serves as General Manager at Daan Gene Co., Ltd. She served as Deputy General Manager at Daan Gene Co., Ltd.since...

取締役

名称	ポジション	在職期間	報酬	所有権
Luo Huang	GM & Director	2.4yrs	CN¥1.27m	データなし
Bin Zhang	Deputy GM	5.6yrs	CN¥1.13m	データなし
Zhengfu Zhu	Independent Director	2.5yrs	CN¥120.00k	データなし
Li Qiang Huang	Supervisor	no data	データなし	データなし
Dianhan Wei	Vice Chairman Of the Board	3.8yrs	データなし	データなし
Wanyu Zhu	Chairman of the Supervisory Board	3.8yrs	データなし	データなし
Teng Hu	Supervisor	3.8yrs	データなし	データなし
Qian Long	Director	2.5yrs	データなし	データなし
Xiaoping Chen	Supervisor	2.5yrs	データなし	データなし
Yunhai Ji	Independent Director	2.5yrs	CN¥120.00k	データなし

2.5yrs

平均在職期間

47.5yo

平均年齢

経験豊富なボード: 002030の取締役会は経験豊富ではない ( 2.5年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Daan Gene マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Daan Gene Co., Ltd., Annual General Meeting, Apr 19, 2024

Less than half of directors are independent

Insufficient new directors

Insufficient new directors

Daan Gene Co., Ltd., Annual General Meeting, Apr 20, 2022

Da an Gene Co., Ltd. of Sun Yat-Sen University Announces Executive Changes

Recent updates

Third quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.035 loss in 3Q 2023)

Health Check: How Prudently Does Daan Gene (SZSE:002030) Use Debt?

Daan Gene Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0.27 profit in 2Q 2023)

Daan Gene Co., Ltd. (SZSE:002030) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected

New minor risk - Share price stability

Daan Gene Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Dividend reduced to CN¥0.015

Daan Gene Co., Ltd. Announces Final Dividend on A Shares for the Year 2023, Payable on 14 June 2024

Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?

First quarter 2024 earnings released: CN¥0.26 loss per share (vs CN¥0.026 profit in 1Q 2023)

Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings released: EPS: CN¥0.075 (vs CN¥3.86 in FY 2022)

Daan Gene Co., Ltd., Annual General Meeting, Apr 19, 2024

Calculating The Fair Value Of Daan Gene Co., Ltd. (SZSE:002030)

Daan Gene Co., Ltd. (SZSE:002030) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Now 21% overvalued

Investor sentiment deteriorates as stock falls 15%

Now 20% overvalued

Daan Gene Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: CN¥0.035 loss per share (vs CN¥0.94 profit in 3Q 2022)

Daan Gene Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

New major risk - Dividend sustainability

Second quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥1.36 in 2Q 2022)

Less than half of directors are independent

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 15%

Daan Gene Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 13, 2023

Investor sentiment deteriorates as stock falls 18%

Full year 2022 earnings released: EPS: CN¥3.95 (vs CN¥2.58 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.94 (vs CN¥0.66 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.36 (vs CN¥0.33 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.34 (vs CN¥0.33 in 2Q 2021)

Insufficient new directors

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of CN¥1.11 per share

Daan Gene Co., Ltd. Proposes Final Cash Dividend on A Shares for the Year 2021, Payable on May 9, 2022

Insufficient new directors

Daan Gene Co., Ltd. Approves Final Dividend for the Year 2021

Daan Gene Co., Ltd., Annual General Meeting, Apr 20, 2022

Daan Gene Co., Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.66 (vs CN¥0.54 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Da An Gene Co., Ltd. of Sun Yat-Sen University Announces Final Dividend Implementation Plan (A Shares) for 2020, Payable on 19 May 2021

First quarter 2021 earnings released: EPS CN¥1.29 (vs CN¥0.21 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.77 (vs CN¥0.10 in FY 2019)

New 90-day low: CN¥29.03

Da an Gene Co., Ltd. of Sun Yat-Sen University Announces Executive Changes

Da An Gene Co., Ltd. of Sun Yat-Sen University to Report Fiscal Year 2020 Results on Mar 31, 2021

Investor sentiment deteriorated over the past week

New 90-day high: CN¥42.15

New 90-day low: CN¥31.98

Third quarter 2020 earnings released: EPS CN¥0.86

First half earnings released

First half earnings released

Da An Gene Co., Ltd. of Sun Yat-Sen University to Report First Half, 2020 Results on Aug 29, 2020

New 90-day high - CN¥40.83

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24